Biological treatments for amfetamine dependence: Recent progress

CNS Drugs

Volumn 21, Issue 10, 2007, Pages 851-869

  Hill, Kevin P ^a   Sofuoglu, Mehmet ^b  

^a MCLEAN HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 7 NITROINDAZOLE; AMITRIPTYLINE; AMPHETAMINE; ATIPAMEZOLE; BACLOFEN; DEXAMPHETAMINE; DONEPEZIL; DRONABINOL; EPLIVANSERIN; ETICLOPRIDE; FLUOXETINE; IMIPRAMINE; LOBELINE; METHAMPHETAMINE; MINOCYCLINE; NALOXONE; NALTREXONE; NICOTINE; PAROXETINE; PRAZOSIN; RILUZOLE; RIMONABANT; SEROTONIN UPTAKE INHIBITOR; TERGURIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VANOXERINE; VIGABATRIN;

ALLELE; CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG DEPENDENCE; DRUG TOLERABILITY; EPIDEMIC; GABAERGIC SYSTEM; GENETIC POLYMORPHISM; HUMAN; INTRAUTERINE GROWTH RETARDATION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; REWARD; SEROTONINERGIC SYSTEM; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AMLODIPINE; AMPHETAMINE-RELATED DISORDERS; ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL THERAPY; GABA AGONISTS; HUMANS; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 34548849802     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721100-00005     Document Type: Review

References (157)

1. Gawin FH, Ellinwood Jr EH. Cocaine and other stimulants: actions, abuse, and treatment. N Engl J Med 1988; 318: 1173-82
2. White FJ, Kalivas PW. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend 1998; 51: 141-53
3. Rothman RB, Partilla JS, Dersch CM, et al. Methamphetamine dependence: medication development efforts based on the dual deficit model of stimulant addiction. Ann N Y Acad Sci 2000; 914: 71-81
4. Bardo MT. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol 1998; 12: 37-67
5. Koob GF. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 1992; 654: 171-91
6. Tzschentke TM, Schmidt WJ. Functional relationship among medial prefrontal cortex, nucleus accumbens, and ventral tegmental area in locomotion and reward. Crit Rev Neurobiol 2000; 14: 131-42
7. Steketee JD. Neurotransmitter systems of the medial prefrontal cortex: potential role in sensitization to psychostimulants. Brain Res Brain Res Rev 2003; 41: 203-28
8. Robbins TW, Everitt BJ. Central norepinephrine neurons and behavior. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1988: 363-72
9. Aston-Jones G, Harris GC. Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology 2004; 47: 167-79
10. Lyness WH, Friedle NM, Moore KE. Increased self-administration of d-amphetamine after destruction of 5-hydroxytryptaminergic neurons. Pharmacol Biochem Behav 1980; 12: 937-41
11. Partilla JS, Dempsey AG, Nagpal AS, et al. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther 2006; 319: 237-46
12. National Institute on Drug Abuse. Methamphetamine abuse and addiction [research report series]. Rockville (MD): National Institutes of Health; 1998 Apr. Publication no. 06-4210
13. Desoxyn®, methamphetamine: product information. North Chicago (IL): Abbott Laboratories, 1996
14. ADDERALL® oral tablets, amphetamine asparate monohydrate, amphetamine sulfate, dextroamphetamine saccharate, dextroamphetamine sulfate oral tablets: product information. Wayne (PA): Shire US Inc., 2006
15. Rawson RA, Huber A, Brethen P. Methamphetamine and cocaine users: differences in characteristics and treatment retention. J Psychoactive Drugs 2000; 32: 233-8
16. Rappley MD. Attention deficit-hyperactivity disorder. N Engl J Med 2005, 173
17. Woodworth T. Statement of Terrance Woodworth, Deputy Director, Office of Diversion Control, Drug Enforcement Administration, before the Committee on Education and the Workforce, Subcommittee on Early Childhood, Youth, and Families, May 16, 2000; Washington, DC
18. Cretzmeyer M, Sarrazin MV, Huber DL, et al. Treatment of methamphetamine abuse: research findings and clinical directions. J Subst Abuse Treat 2003; 24 (3): 267-77
19. Garreau J. A dose of genius: 'smart pills' are on the rise. But is taking them wise? Washington Post 2006 June 11; Sect. D: 1
20. Meredith CW, Jaffe C, Ang-Lee K, et al. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 2005; 13: 141-54
21. United Nations Office for Drug Control and Crime Prevention. World drug report 2000 [online]. Available from URL: http://www.whitehousedrugpolicy.gov/ publications/policy/ndcs03/table71.html [Accessed 2006 Nov 21]
22. Office of Applied Studies, Substance Abuse and Mental Health Services Administration. Amphetamine and methamphetamine emergency department visits 1995-2002 (DAWN report) [online]. Available from URL: http://dawninfo.samsha. gov/old_dawn/pubs_94_02/shortreports/ [Accessed 2006 November 21]
23. Office of Applied Studies. Results from the 2004 National survey on drug use and health: national findings. Rockville (MD): Substance Abuse and Mental Health Services Administration, 2005. DHHS publication no. SMA 05-4062, NSDUH series H-28
24. Rawson RA, Anglin MD, Ling W. Will the methamphetamine problem go away? J Addict Dis 2002; 21: 5-19
25. National Drug Intelligence Center. Information bulletin: children at risk [online]. Available from URL: http://www.usdoj.gov/ndic/pubs1/1466 [Accessed 2006 November 21]
26. Kolecki P. Inadvertent methamphetamine poisoning in pediatric patients. Pediatr Emerg Care 1998; 14: 385-7
27. Plessinger MA. Prenatal exposure to amphetamines: risks and adverse outcomes in pregnancy. Obstet Gynecol Clin North Am 1998; 25: 119-38
28. Blumenthal RN, Kral AH, Gee L, et al. Trends in HIV seroprevalence and risk among gay and bisexual men who inject drugs in San Francisco, 1988 to 2000. J Acquir Immune Defic Syndr 2001; 28: 264-9
29. Harris NV, Thiede H, McGough JP, et al. Risk factors for HIV infection among injection drug users: results of blinded surveys in drug treatment centers, King County, Washington 1988-1991. J Acquir Immune Defic Syndr 1993; 6: 1275-82
30. Missale C, Walsh SR, Robinson SW, et al. Dopamine receptors: from structure to function. Pharmacol Rev 1998; 78: 189-225
31. Geis LS, Smith DG, Smith FL, et al. Tyrosine influence on amphetamine self-administration and brain catecholamines in the rat. Pharmacol Biochem Behav 1986; 25: 1027-33
32. Baumann MH, Ayestas MA, Sharpe LG, et al. Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate. J Pharmacol Exp Ther 2002; 301: 1190-7
33. Izzo E, Orsini C, Koob GF, et al. A dopamine partial agonist and antagonist block amphetamine self-administration in a progressive ratio schedule. Pharmacol Biochem Behav 2001; 68: 701-8
34. 3 dopamine receptors are down-regulated in amphetamine sensitized rats and their putative antagonists modulate the locomotor sensitization to amphetamine. Brain Res 2003; 972: 159-67
35. Tzschentke TM, Schmidt WJ. Glutamatergic mechanisms in addiction. Mol Psychiatry 2003; 8: 373-82
36. B agonists in the treatment of psychostimulant addiction. Alcohol Alcohol 2002; 37: 478-84
37. Blein S, Hawrot E, Barlow P. The metabotropic GABA receptor: molecular insights and their functional consequences. Cell Mol Life Sci 2000; 57: 635-50
38. Sofuoglu M, Kosten TR. Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opinion Emerg Drugs 2006; 11: 91-8
39. Ranaldi R, Poeggel K. Baclofen decreases methamphetamine self-administration in rats. Neuroreport 2002; 13: 1107-10
40. Brebner K, Ahn S, Phillips AG. Attenuation of D-amphetamine self-administration by baclofen in the rat: behavioral and neurochemical correlates. Psychopharmacology (Berl) 2005; 177: 409-17
41. Li SM, Yin LL, Ren YH, et al. GABAB receptor agonist baclofen attenuates the development and expression of d-amphetamine-induced place preference in rats. Life Sci 2001; 70: 349-56
42. Bartoletti M, Gubellini C, Ricci F, et al. Baclofen blocks the development of sensitization to the locomotor stimulant effect of amphetamine. Behav Pharmacol 2005; 16: 553-8
43. Steketee JD. Cortical mechanisms of cocaine sensitization. Crit Rev Neurobiol 2005; 17: 69-86
44. Gerasimov MR, Ashby Jr CR, Gardner EL, et al. Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse 1999; 34: 11-9
45. Bjijou Y, De Deurwaerdere P, Spampinato U, et al. D-amphetamine-induced behavioral sensitization: effect of lesioning dopaminergic terminals in the medial prefrontal cortex, the amygdala and the entorhinal cortex. Neuroscience 2002; 109: 499-516
46. Kim JH, Austin JD, Tanabe L, et al. Activation of group II mGlu receptors blocks the enhanced drug taking induced by previous exposure to amphetamine. Eur J Neurosci 2005; 21: 295-300
47. Tzschentke TM. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 1998; 56: 613-72
48. da Silva AL, Hoffman A, Dietrich MO, et al. Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. Neuropsychobiology 2003; 48: 27-30
49. Itzhak Y, Martin JL. Effect of riluzole and gabapentin on cocaine- and methamphetamine-induced behavioral sensitization in mice. Psychopharmacology (Berl) 2000; 151: 226-33
50. Bradberry CW. Cocaine sensitization and dopamine mediation of cue effects in rodents, monkeys, and humans: areas of agreement, disagreement, and implications for addiction. Psychopharmacology 2007; 191: 705-17
51. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev 1997; 25: 192-216
52. Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci 2004; 1025: 279-87
53. Boireau A, Meunier M, Imperato A. Ouabain-induced increase in dopamine release from mouse striatal slices antagonized by riluzole. J Pharm Pharmacol 1998; 50: 1293-7
54. Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology. New York: Oxford University Press, 2003
55. 1-adrenergic receptors in acute and sensitized locomotor effects of d-amphetamine, cocaine, and GBR 12783: influence of preexposure conditions and pharmacological characteristics. Synapse 2002; 43: 51-61
56. 2A and α1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. Eur J Neurosci 2004; 20: 3073-84
57. 2- adrenoreceptor antagonist atipamezole reduces the development and expression of D-amphetamine-induced behavioural sensitization. Arch Pharmacol 2003; 367: 274-80
58. 2A- Adrenoreceptors regulate D-amphetamine-induced hyperactivity and behavioural sensitization in mice. Eur J Pharmacol 2005; 517: 74-83
59. Colussi-Mas J, Panayi F, Scarna H, et al. Blockade of β-adrenergic receptors prevents amphetamine-induced behavioural sensitization in rats: a putative role of the bed nucleus of the stria terminalis. Int J Neuropsychopharmacol 2005; 8: 1-13
60. Leccese AP, Lyness WH. The effects of putative 5-hydroxytryptamine active agents on d-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesions. Brain Res 1984; 303: 153-62
61. Yu DSL, Smith FL, Smith DG. Fluoxetine-induced attenuation of amphetamine self-administration in rats. Life Sci 1986; 39: 1383-8
62. Kokkinidis L, Zacharko RM, Predy PA. Post-amphetamine depression of self-stimulation responding from the substantia nigra: reversal by tricyclic antidepressants. Pharamacol Biochem Behav 1980; 13: 379-83
63. Salomon L, Lanteri C, Glowinski J. Behavioral sensitization to amphetamine results from an uncoupling between noradrenergic and serotonergic neurons. Proc Natl Acad Sci 2006; 103: 7476-81
64. 1A receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats. Psychopharmacology 2005; 178: 133-42
65. Gardner EL, Schiffer WK, Horan BA, et al. Gamma vinyl GABA, an irreversible inhibitor of GABA transaminase, alters the acquisition and expression of cocaine-induced sensitization in male rats. Synapse 2002; 46: 240-50
66. 9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamines in rats. Eur J Pharmacol 1999; 365: 133-42
67. Anggadiredja K, Nakamichi M, Hiranita T, et al. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology 2004; 29: 1470-8
68. Hiranita T, Nawata Y, Sakimura K, et al. Suppression of methamphetamine-seeking behavior by nicotinic agonists. Proc Natl Acad Sci U S A 2006; 103: 8523-7
69. Harrod SB, Dwoskin LP, Crooks PA, et al. Lobeline attenuates d-amphetamine self-administration in rats. J Pharmacol Exp Ther 2001; 298: 172-9
70. Siegal D, Erickson J, Varoqui H, et al. Brain vesicular acetylcholine transporter in human users of drugs of abuse. Synapse 2004; 52: 223-32
71. Hikida T, Kitabatake Y, Pastan I, et al. Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine. Proc Natl Acad Sci U S A 2003; 100: 6169-73
72. Sesack SR, Pickel VM. Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area: multiple substrates for opioid-dopamine interactions. J Neurosci 1992; 12: 1335-50
73. Kubota Y, Inagaki S, Kito S, et al. Ultrastructural evidence of dopaminergic input to enkephalinergic neurons in rat neostriatum. Brain Res 1986; 367: 374-8
74. Olive MF, Koenig HN, Nannini MA. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. J Neurosci 2001; 21: RC184
75. Hooks MS, Jones GH, Liem BJ, et al. Sensitization and individual differences to IP amphetamine, cocaine, or caffeine following repeated intracranial amphetamine infusions. Pharmacol Biochem Behav 1992; 43: 815-23
76. Trujillo KA, Belluzzi JD, Stein L. Naloxone blockade of amphetamine place preference conditioning. Pharmacology 1991; 104: 265-74
77. Chiu CT, Ma T, Ho IK. Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone. Brain Res Bull 2005; 67: 100-9
78. Anggadiredja K, Sakimura K, Hiranita T, et al. Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: a possible mechanism for the dissociation of primary and secondary reward. Brain Res 2004; 1021: 272-6
79. Harrigan SE, Downs DA. Continuous intravenous naltrexone effects on morphine self-administration in rhesus monkeys. J Pharmacol Exp Ther 1978; 204: 481-6
80. Itzhak Y, Ali SF. Role of nitrergic system in behavioral and neurotoxic effects of amphetamine analogs. Pharmacol Ther 2006; 109: 246-62
81. Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggest role as intercellular messenger in the brain. Nature 1988; 336: 385-8
82. Itzhak Y. Modulation of cocaine- and methamphetamine-induced behavioral sensitization by inhibition of brain nitric oxide synthase. J Pharmacol Exp Ther 1997; 282: 521-7
83. Vaupel DB, Kimes AS, London ED. Comparison of 7-nitroindazole with other nitric oxide synthase inhibitors as attenuators of opioid withdrawal. Psychopharmacology (Berl) 1995; 118: 361-8
84. Vaupel DB, Kimes AS, London ED. Nitric oxide synthase inhibitors: preclinical studies of potential use for treatment of opioid withdrawal. Neuropsychopharmacology 1995; 13: 315-22
85. Kofman O, van Embden S, Alpert C, et al. Central and peripheral minocycline suppresses motor acitivity in rats. Pharmacol Biochem Behav 1993; 44: 397-402
86. Kofman O, Klein E, Newman M, et al. Inhibition by antibiotic tetracyclines of rat cortical noradrenergic adenylate cyclase and amphetamine-induced hyperactivity. Pharmacol Biochem Behavior 1990; 37: 417-24
87. Hashimoto K, Tsukada H, Nishiyama S, et al. Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a positron emission tomography study in conscious monkeys. Biol Psychiatry 2007; 61: 577-81
88. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 2001; 98: 14669-74
89. Hiranita T, Anggadiredja K, Fujisaki C, et al. Nicotine attenuates relapse to methamphetamine-seeking behavior (craving) in rats. Ann N Y Acad Sci 2006; 1025: 504-7
90. Fukami G, Hashimoto K, Koike K, et al. Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res 2004; 1016: 90-5
91. Peck JA, Reback CJ, Yang X, et al. Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men. J Urban Health 2005; 82: 100-8
92. Batki SL, Moon J, Bradley M, et al. Fluoxetine in methamphetamine dependence: a controlled trial. Preliminary analysis. In: LS Harris, editor. Problems of drug dependence 1999. Proceedings of the 61st Annual Scientific Meeting of the College on Problems of Drug Dependence, Inc. (NIDA research monograph 180, NIH publication no. 00-4737). Washington, DC: Government Printing Office, 2000: 235
93. Piasecki MP, Steinagel GM, Thienhaus OJ. An exploratory study: the use of paroxetine for methamphetamine craving. J Psychoactive Drugs 2003; 34: 301-4
94. Shoptaw S, Huber A, Peck J, et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006; 85: 12-8
95. Galloway GP, Newmeyer J, Knapp T, et al. A controlled trial of imipramine for the treatment of methamphetamine dependence. J Subst Abuse Treat 1996; 13: 493-7
96. Tennant Jr RS, Tarver A, Pumphrey E, et al. Double-blind comparison of desipramine and placebo for treatment of phenicyclidine or amphetamine dependence. NIDA Res Monogr 1986; 67: 310-7
97. Jittiwutikan J, Srisurapanont M, Jarusuraisin N. Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study. J Med Assoc Thai 1997; 80: 587-91
98. Srisurapanont M, Jarusuraisin N, Jittiwutikan J. Amphetamine withdrawal: II. A placebo-controlled, randomised, double-blind study of amineptine treatment. Aust N Z J Psychiatry 1999; 33: 94-8
99. Newton TF, Roache JD, De La Garza II R. Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology 2005; 182: 426-35
100. Elkashef AM, Rawson RA, Smith E, et al. Bupropion for the treatment of methamphetamine dependence [oral presentation]. 68th Annual Scientific Conference of the College on Problems of Drug Dependence; 2006 Jun 17-22; Scottsdale (AZ)
101. McGregor C, White JM, Srisurapanont M, et al. Open-label pilot trials of mirtazapine and modafinil in inpatient methamphetamine withdrawal: symptoms and sleep patterns [poster]. 67th Annual Scientific Conference of the College on Problems of Drug Dependence; 2005 Jun 18-23; Orlando (FL)
102. Johnson BA, Ait-Daoud N, Elkashef AM, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int J Neuropsychopharmacol 2007. Epub ahead of print
103. Cousins MS, Roberts DC, De Wit H. GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend 2002; 65: 209-20
104. Shoptaw S, Yang X, Rotheram-Fuller EJ, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 2003; 64: 1440-8
105. Haney M, Hart C, Collins ED, et al. Smoked cocaine discrimination in humans: effects of gabapentin. Drug Alcohol Depend 2005; 80: 53-61
106. Johnson BA, Roache JD, Ait-Daoud N, et al. Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 123-30
107. Heinzerling KG, Shoptaw S, Peck JA, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006; 85: 177-84
108. Brodie JD, Figueroa E, Laska EM, et al. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of the treatment of methamphetamine and/or cocaine addiction. Synapse 2005; 50: 261-5
109. Rush CR, Stoops WW, Hays LR, et al. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J Pharmacol Exp Ther 2003; 306: 195-204
110. Lile JA, Stoops WW, Vansickel AR, et al. Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of d-amphetamine in humans. Neuropsychopharmacology 2005; 30: 2103-14
111. Saxon AJ, Jaffe C, Meredith CW, et al. Open-label trial of risperidone for methamphetamine dependence [poster]. 67th Annual Scientific Conference of the College on Problems of Drug Dependence; 2005 Jun 18-23; Orlando (FL)
112. Reid MS, Palamar J, Falmmino F, et al. A double-blind, placebo-controlled assessment of aripiprazole effects on methamphetamine craving: inpatient longitudinal and cue reactivity studies [oral presentation]. 68th Annual Scientific Conference of the College on Problems of Drug Dependence; 2006 Jun 17-22; Scottsdale (AZ)
113. Pani L, Carboni S, Kusmin A, et al. Nimodipine inhibits cocaine-induced dopamine release and motor stimulation. Eur J Pharmacol 1990; 176: 245-6
114. Pucilowski O, Plaznik A, Overstreet DH. Isradipine suppresses amphetamine-induced conditioned place preference and locomotor stimulation in the rat. Neuropsychopharmacology 1995; 12: 239-44
115. Johnson BA, Roache JD, Bordnick PS, et al. Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: a preliminary study. Psychopharmacology 1999; 144: 295-300
116. Batki SL, Moon J, Delucchi K, et al. Amlodipine treatment of methamphetamine dependence, a controlled outpatient trial: preliminary analysis [abstract]. Drug Alcohol Depend 2001; 63 Suppl. 1: 12
117. Taneja I, Diedrich A, Black BK, et al. Modafinil elicits sympathomedullary activation. Hypertension 2005; 45: 612-8
118. Jasinki DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000; 14: 53-60
119. Rush CR, Kelly TH, Hays LR, et al. Acute behavioral and physiological effects of modafinil in drug abusers. Behav Pharmacol 2002; 13: 105-15
120. Grabowski J, Shearer J, Merrill J, et al. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 2004; 29: 1439-64
121. Fleming PM, Roberts D. Is the prescription of amphetamine justified as a harm reduction measure? J R Soc Health 1994; 114: 127-31
122. Pates R, Coombes N, Ford N. A pilot programme in prescribing dexamphetamine for amphetamine users (Pt 1). J Subst Misuse 1996; 1: 80-4
123. McBride AJ, Sullivan G, Blewett AE, et al. Amphetamine prescribing as a harm reduction measure: a preliminary study. Addict Res 1997; 5: 95-112
124. Klee H, Wright S, Carnath T, et al. The role of substitute therapy in the treatment of problem amphetamine use. Drug Alcohol Rev 2001; 20: 417-29
125. Shearer J, Wodak A, Mattick RP, et al. Pilot randomised controlled study of dexamphetamine for amphetamine dependence. Addiction 2001; 96: 1289-96
126. Spielewoy C, Biala G, Roubert C, et al. Hypolocomotor effects of acute and daily d-amphetamine in mice lacking the dopamine transporter. Psychopharmacology 2001; 159: 2-9
127. Palmer AA, Verbitsky M, Suresh R, et al. Gene expression differences in mice divergently selected for methamphetamine sensitivity. Mamm Genome 2005; 16: 291-305
128. Berrettini WH, Lerman CE. Pharmacotherapy and pharmacogenetics of nicotine dependence. Am J Psychiatry 2005; 162: 1441-51
129. Wolf CR, Smith G, Smith RL. Science, medicine, and the future: pharmacogenetics. BMJ 2000; 320: 987-90
130. Volkow ND, Fowler JS, Wang G, et al. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord 2002; 6 Suppl. 1: S31-43
131. Stein MA, Waldman ID, Sarampote CS, et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 2005; 30: 1374-82
132. Kirley A, Hawi Z, Daly G, et al. Association of the 480bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet 2003; 12: 50-4
133. Gelernter J, Kranzler HR, Satel RA, et al. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology 1994; 11: 195-200
134. Cubells JF, Kranzler HR, McCance-Katz E, et al. A haplotype at the DBH locus, associated with low plasma dopamine β-hydroxylase activity, also associates with cocaine-induced paranoia. Mol Psychiatry 2000; 5: 56-63
135. Li T, Chen C, Hun X, et al. Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet 2004; 129: 120-4
136. Lott DC, Kim SJ, Cook Jr EH. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 2005; 30: 602-9
137. Lott DC, Kim SJ, Cook Jr EH. Serotonin transporter genotype and acute subjective response to amphetamine. Am J Addict 2006; 15: 327-35
138. Veenstra-Vanderweele J, Qaadir A, Palmer AA, et al. Association of the casein kinase 1 epsilon gene and subjective response to D-amphetamine. Neuropsychopharmacology 2006; 31: 1056-63
139. Greengard P. The neurobiology of slow synaptic transmission. Science 2001; 294: 1024-30
140. 158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 2003; 100: 6186-91
141. 2A receptor gene variants. Am J Med Genet 2005; 139: 42-4
142. Winsburg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 1999; 38: 1474-7
143. Seeger G, Schloss P, Schmidt MH. Marker gene polymorphisms in the hyperkinetic disorder: predictors of clinical response to treatment with methylphenidate? Neurosci Lett 2001; 313: 45-8
144. Tsai SJ, Cheng CY, Shu LR, et al. No association for D2 and D4 dopamine receptor polymorphisms and methamphetamine abuse in Chinese males. Psychiatr Genet 2002; 12: 29-33
145. Loo SK, Specter E, Smolen A, et al. Functional effects of the DAT1 polymorphism on EEG measures in ADHD. J Am Acad Child Adolesc Psychiatry 2003; 42: 986-93
146. Ujike H, Harano M, Inada T, et al. Nine or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J 2003; 3: 242-7
147. Hamarman S, Fossella J, Ulger C, et al. Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. J Child Adolesc Psychopharmacol 2004; 14: 564-74
148. Ide S, Kobayashi H, Tanaka K, et al. Gene polymorphisms of the mu opioid receptor in methamphetamine abusers. Ann N Y Acad Sci 2004: 1025, 324
149. Kobayashi H, Ide S, Hasegawa J, et al. Study of association between α-synuclein gene polymorphism and methamphetamine psychosis/dependence. Ann N Y Acad Sci 2004; 1025: 325-34
150. Koizumi H, Hashimoto K, Kumakiri C, et al. Association between the glutathione S-transferase M1 gene deletion and female methamphetamine abusers. Am J Med Genet B Neuropsychiatr Genet 2004; 126B: 43-5
151. Hashimoto T, Hashimoto K, Matsuzawa D, et al. A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. Am J Med Genet B Neuropsychiatr Genet 2005; 135B: 5-9
152. Ikeda M, Iwata N, Suzuki T, et al. Positive association of AKT1 haplotype to Japanese methamphetamine use disorder. Int J Neuropsychopharmacol 2005; 8: 1-5
153. Itoh K, Hashimoto K, Shimuzi E, et al. Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan. Am J Med Genet B Neuropsychiatr Genet 2005; 132B: 70-3
154. Morita Y, Ujike H, Tanaka Y, et al. The X-box binding protein (XBP1) gene is not associated with methamphetamine dependence. Neurosci Lett 2005; 383: 194-8
155. A receptor γ2 subunit gene (GABRG2) and methamphetamine use disorder. Pharmacogenomics J 2005; 5: 89-95
156. Ohgake S, Hashimoto K, Shimizu E. Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis. Addict Biol 2005; 10: 145-8
157. Ide S, Kobayashi H, Ujike H, et al. Linkage disequilibrium and association with methamphetamine dependence/psychosis of μ-opioid receptor gene polymorphisms. Pharmacogenomics J 2006; 6: 179-88